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Available online 27 April 2016Background:Metabotropic glutamate receptor 3 (mGlu3, mGluR3), encoded by GRM3, is a risk gene for schizo-
phrenia and a therapeutic target. It is unclear whether expression of the receptor is altered in the disorder or re-
lated to GRM3 risk genotype. Antibodies used to date to assess mGlu3 in schizophrenia have not been well
validated.
Objective: To characterise six commercially available anti-mGlu3 antibodies for use in human brain, and then
conduct a semi-quantitative study of mGlu3 immunoreactivity in schizophrenia.
Methods: Antibodies tested using Grm3−/− and Grm2−/−/3−/−mice and transfected HEK293T/17 cells.Western
blotting on membrane protein isolated from superior temporal cortex of 70 patients with schizophrenia and 87
healthy comparison subjects, genotyped for GRM3 SNP rs10234440.
Results:One (out of six) anti-mGlu3 antibodies was fully validated, a C-terminal antibodywhich detectedmono-
meric (~100 kDa) and dimeric (~200 kDa)mGlu3. A second, N-terminal, antibody detected the 200 kDa band but
also produced non-speciﬁc bands. Using the C-terminal antibody forwestern blotting in human brain,mGlu3 im-
munoreactivity was found to decline with age, and was affected by pH and post mortem interval. There were no
differences inmonomeric or dimericmGlu3 immunoreactivity in schizophrenia or in relation to GRM3 genotype.
The antibody was not suitable for immunohistochemistry.
Interpretation: These data highlight the value of knockout mouse tissue for antibody validation, and the need for
careful antibody characterisation. The schizophrenia data show that involvement of GRM3 in the disorder and its
genetic risk architecture is not reﬂected in totalmembranemGlu3 immunoreactivity in superior temporal cortex.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Antibody validation1. Introduction
Group II metabotropic glutamate receptors comprise mGlu2 and
mGlu3, encoded by GRM2 and GRM3 respectively. They are G
protein-coupled receptors, serving primarily as presynaptic
autoreceptors, involved in many facets of synaptic plasticity and
brain function (Niswender and Conn, 2010). These receptors are im-
plicated in schizophrenia as part of the broader glutamatergic hy-
potheses of the disorder, in part driven by pharmacological studiesniversity of Oxford, Warneford
. This is an open access article undershowing that group II mGlu agonists can ameliorate deﬁcits caused
by NMDA receptor antagonism (Moghaddam and Adams, 1998; for
review see Moreno et al., 2009; Moghaddam and Javitt, 2012). This
work fostered development of mGlu2/3 agonists as potential anti-
schizophrenia treatments, with a high-proﬁle positive clinical trial
for one such drug, pomaglumetad methionil (Patil et al., 2007).
Though this ﬁnding was not replicated, interest in group II mGluRs
in schizophrenia and as antipsychotic drug targets has persisted
(Lyon et al., 2011b; Fell et al., 2012; Vinson and Conn, 2012; Lane
et al., 2013; Ellaithy et al., 2015; De Filippis et al., 2015; Pritchett
et al., 2015;Walker and Conn, 2015), and a recent secondary analysis
of the clinical trials suggests that pomaglumetadmethionil may have
antipsychotic efﬁcacy early in the disease and in patients previously
exposed to D2 dopamine antagonists (Kinon et al., 2015).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mGluRs in schizophrenia is complemented by increasing evidence that
GRM3 is a risk gene for the disorder (Harrison et al., 2008). Initially re-
ported in candidate gene studies (Egan et al., 2004), the evidence is now
markedly enhanced by the ﬁnding that the GRM3 locus is genome-wide
signiﬁcant for schizophrenia (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014). Notably, the signal is intra-
genic, supporting the interpretation that the genetic association is to
the gene itself, and that it may operate by altering GRM3 regulation
and expression (Sartorius et al., 2008; Kleinman et al., 2011; Harrison,
2015).
As part of the characterisation of GRM3/mGlu3 in schizophrenia,
several studies have measured expression of the gene in brain tissue
(see Harrison et al., 2008; Hu et al., 2015). Studies of GRM3 mRNA do
not show clear differences between schizophrenia cases and controls
(Ohnuma et al., 1998; Richardson-Burns et al., 2000; Egan et al., 2004;
Bullock et al., 2008; Gonzalez-Maeso et al., 2008; Kim et al., 2012) al-
though there may be a modest increase in prefrontal cortex (Sartorius
et al., 2008). The latter authors also reported that a GRM3 risk SNP
was associated with decreased expression of a transcript isoform
which lacked exon 4 and predicted to encode an mGlu3 variant with a
novel C-terminus (Sartorius et al., 2006, 2008). With regard to studies
of mGlu3 immunoreactivity, the data are more variable (see Table 1
for summary of existing studies). A major consideration is that most
studies have used antibodies which cross react withmGlu2, or antibod-
ies which have not been well characterised to demonstrate their speci-
ﬁcity for mGlu3. The one exception is the antibody generated by Corti
et al. (2007), which in Grm3−/−mice showed selectivity. With this an-
tibody, they then demonstrated a reduction of mGlu3 dimer in prefron-
tal cortex in schizophrenia.
Given the renewed, genomically-driven, focus on GRM3, the ques-
tion ofmGlu3 expression in schizophrenia, and its potentialmodulation
by schizophrenia risk genotype, requires a clearer answer than the prior
studies permit. Firstly, by using antibodies that have been sufﬁciently
well characterised. To this end, we have tested a range of anti-mGlu3
antibodies, using brain tissue from Grm3−/− mice, and from
Grm2−/−/3−/− mice, complemented by transfection of cells with
human GRM3 cDNA. We also tested a novel antibody directed at the
previously-reported novel mGlu3 variant (mGlu3Δ4; Sartorius et al.,Table 1
Prior western blot studies of mGlu3 in schizophrenia, showing main methodological features a
Study Antibody Antibody validation Sample Sample preparati
and methoda
Crook et al.
(2002)
Anti-mGlu2/3
(Chemicon)
Pre-absorption with
mGlu2/3 peptide abolished
immunoreactivity.
20 SCZ,
20
CON
Membranes; 7.5%
PA gels and 50 μg
protein
(duplicates).
Gupta et al.
(2005)
Anti-mGlu2/3
(Upstate
Bio-technology)
No data presented; paper
refers to earlier papers, but
the latter used a Chemicon
mGlu2/3 antibody (with
peptide pre-absorption used
as the control).
16 SCZ,
9 CON
Total homogenat
5% β-ME and
heated at 95 °C fo
4 min; 7.5% PA ge
and 40 μg protein
(duplicates).
Corti et al.
(2007)
Anti-mGlu3,
raised against
residues 16–35
in mouse
mGlu3.
Tested using GRM3
cDNA-transfected CHO cells,
and grm3−/−mouse brain.
20 SCZ,
35
CON
Membranes; 20
mM DTT, heated
60 °C for 3 min; 8
PA gels 40 μg
protein
(triplicates).
Ghose et al.
(2009)
Anti-mGlu3
(Abcam)
No data presented; the
authors refer to a prior
paper, but the latter does not
provide clarity.
15 SCZ,
15
CON
Total homogenat
10% PA gels and 2
μg protein
(duplicates).
a DTT: dithiothreitol. ME: mercaptoethanol. PA: polyacrylamide.
b BA: Brodmann area. BA9/46: dorsolateral prefrontal cortex. BA10: frontal pole. BA11, BA322008). Having characterised the antibodies, we used a validated C-
terminal anti-mGlu3 antibody for a semi-quantitative immunoblot
study of membrane protein from superior temporal cortex from a series
of over 150 patients with schizophrenia and comparison subjects, who
were genotyped for a GRM3 risk single nucleotide polymorphism
(SNP). The superior temporal cortex is implicated in schizophrenia in
terms of alterations in volume (Sun et al., 2009), connectivity (Lee
et al., 2009), cytoarchitecture (Eastwood and Harrison, 2003; Beasley
et al., 2009), and gene expression (Burnet et al., 1996; Eastwood and
Harrison, 2005; Schmitt et al., 2011).
2. Materials and methods
2.1. Mouse brain tissue
Brains were taken from adult Grm3−/− knockout mice, Grm2−/−/
3−/− double knockout mice, and wild-type mice (Lyon et al., 2008,
2011a; De Filippis et al., 2015), snap frozen, and stored at−80 °C. For
protein isolation, a small piece of frontal tissue was cut with a clean
razor blade, weighed, and homogenised using membrane extraction
buffer and a Dounce homogeniser on ice (n= 3 adult female mice per
genotype).
2.2. Human brain tissue
The demographic details of the human brains used for the main
quantitative study are summarised in Table 2 (‘Full series’; for explana-
tion of the ‘Matched series’ see Section 2.9).
The brains were collected at the National Institute for Mental Health
(NIMH) and are from a series described and used in previous studies
(e.g. Lipska et al., 2006; Eastwood et al., 2010). Brieﬂy, the tissuewas ob-
tained with informed consent from the legal next of kin under NIMH
protocol no. 90-M-0142. Diagnoses weremade by independent reviews
of clinical records by two board-certiﬁed psychiatrists using DSM-IV
criteria. Control subjects were designated as such based on a standard-
ized screening interview with next of kin, in addition to a review of all
available medical records and investigators at the medical examiners'
ofﬁces. Brains were examined macroscopically and microscopically by
a board-certiﬁed neuropathologist, and all subjects with signiﬁcantnd key ﬁndings.
on Brain areab Loading
controls
Bands measured Main ﬁndings
BA46 Two internal
controls in
each blot.
~100 kDa No group
difference.
Negative
correlation with
age in controls.
es;
r
ls
BA9, 11, 32
and 46; n.
accumbens,
putamen,
caudate
None stated. ~100–110 kDa Increase in BA46 in
schizophrenia.
at
%
BA10 β-actin and
Ponceau S.
Each gel also
contained
two internal
standards.
~100 and ~200 kDa bands in
cells and WT mouse brain;
not seen in grm3−/−mouse.
Human brain: bands at
~200 kDa and doublet at
~95/100 kDa.
200 kDa band
reduced in
schizophrenia.
Negative
correlations with
age for 200 kDa and
100 kDa bands.
es;
0
Prefrontal,
temporal
and motor
cortex.
β-tubulin Monomer; Molecular
weight not speciﬁed.
mGlu3 decreased in
prefrontal cortex in
schizophrenia.
: medial prefrontal cortex.
Table 2
Demographic details of subjects studied.
Full series ‘Matched’ seriesa
Controls Schizophrenia Controls Schizophrenia
Number 87 70 63 46
Sex (male/female) 59/28 43/27 46/17 32/14
Age (years) 42.0 (14.7) 51.6 (15.5)⁎ 42.7 (14.3) 46.7 (13.9)
Race (C/AA/other)b 28/52/7 26/40/4 21/38/4 18/25/3
Hemisphere (R/L/not known)c 15/59/13 9/55/6 9/46/8 7/36/3
Brain weight (grams) 1372 (152) 1327 (161) 1377 (151) 1351 (153)
Brain pH 6.55 (0.33) 6.37 (0.29)⁎ 6.56 (0.21) 6.47 (0.23)
Post mortem interval (hours) 32.5 (14.5) 40.1 (19.8)⁎ 33.5 (14.4) 34.6 (13.9)
Smoker (yes/no/not known) 21/63/3 51/19/0 16/44/3 37/9/0
Suicide (yes/no/not known) 0/87/0 11/58/1 0/63/0 10/36/0
Age at onset of illness (years) – 23.3 (9.1) – 20.5 (6.0)
Duration of illness (years) – 28.3 (14.2) – 26.3 (12.7)
Antipsychotic detected (yes/no) – 42/28 – 27/19
Daily CPZ equivalents (grams)d – 600 (100−3000) – 600 (100–3000)
rs10234440 genotype (TT/TC/CC)e 65/19/2 56/12/2 46/15/1 38/7/1
Values are mean (SD).
⁎ Cases vs. controls, p b 0.01 (t-test).
a Limited to subjects aged b72 years, with postmortem interval b72h, andbrain pHbetween 6.1 and 6.9. Cases and controls in this ‘matched’ series donot differ in age, pHor PMI (allp N
0.05).
b C: Caucasian. AA: African American.
c R: right. L: left.
d CPZ: chlorpromazine. Range in brackets.
e Not available for one control subject.
20 A. García-Bea et al. / Schizophrenia Research 177 (2016) 18–27pathological features were excluded (Lipska et al., 2006). Toxicological
analysis was conducted for each case using blood and/or brain speci-
mens for drugs of abuse and medications. Control cases with ethanol
levels above 0.05 g/dL, or positive for any illicit drugs, or medications
above therapeutic levels, were excluded. For this study, a block of supe-
rior temporal gyrus (Brodmann area 22) was dissected from a frozen
coronal slab of each brain, with white matter trimmed using a dental
drill. The block was maintained at−80 °C until protein extraction, per-
formed as described for mouse brain tissue.
In addition, we used frozen tissue blocks or sections from several
‘test’ brains provided by the Stanley Medical Research Institute for
some pilot studies during validation of the antibodies, and for mGlu3
detection in brain regions other than the superior temporal cortex.
2.3. Genotyping
Genotyping of rs10234440 (T/C) was performed on DNA extracted
from the superior temporal cortex tissue, using a Taqman assay (ID
C_341072_10) and a 7900HT real-time PCR system. This SNP lies within
the GRM3 region showing genome-wide association to schizophrenia
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014) and is also in linkage disequilibrium with another
SNP, rs2228595, previously shown to have an effect on expression of a
GRM3 mRNA isoform (GRMΔ3Δ4) though not on full-length GRM3
mRNA (Sartorius et al., 2008).
2.4. Cell culture and transient transfection
The human embryonic kidney cell line HEK293T/17 (ATCC CRL-
11268) was maintained in Dulbbeco's modiﬁed Eagle's medium
(DMEM; Sigma D6545) containing 4.5 g/L glucose and supplemented
with 10% fetal bovine serum (FBS) (Sigma F9665) and 4 mM L-
glutamine (Sigma G7513). Cells were seeded at a density of
5 × 104 cells/cm2 in Chamber Slides (Nunc™ Lab-Tek™ II Chamber
Slide™ System) for immunocytochemistry or T-75 ﬂasks for western
blots. Cellswere grown for 24 h and then transfectedwith a PCI neo con-
struct containing the open reading frame for either full length human
GRM3 or GRM3Δ4 using a standard polyethylenimine (Aldrich
40,872-7 averageMW25000) protocol. Brieﬂy, human GRM3 construct
(533.33 ng/μL; 200ng/cm2)wasmixedwith 20% glucose at a ratio of 1:3glucose to DNA, PEI (5.6mg/mL) was then added to themix at a ratio of
1:3.3 (PEI to DNA glucose) and incubated for 5 min at room tempera-
ture. The mixture was added to fresh culture media (DMEM 4.5 g/L glu-
cose, 10% FBS and 2mM L-glutamine) and cells were incubated for 24 h,
following which, the media was exchanged. Cells were incubated for a
further 24 h before harvesting.
2.5. Antibodies
We tested several commercially available anti-mGlu3 antibodies
(Table 3). The Table also lists the other antibodies used.
In addition, a polyclonal antibody was generated (Cambridge Re-
search Biochemicals, Cambridge, UK) to the novel C-terminus of
mGlu3Δ4. The antibody was raised against the peptide sequence
TQGSHHPVTPEEC which corresponds to amino acids 465–478 of the
variant protein. Crude antiserum was puriﬁed by afﬁnity chromatogra-
phy and used for western blot at 1:500. For some experiments, the pep-
tide was used as a blocking peptide at 0.03 mg/mL (N50 × the
concentration of the antibody).
2.6. Western blotting
Total membrane protein from cells, mouse and human brain sam-
pleswas extracted using a kit (Biovision Incorporated,Milipitas, Califor-
nia, USA), according to manufacturer's instructions, with minor
modiﬁcations (viz. addition of 100 μMiodoacetamide duringhomogeni-
sation to prevent receptor aggregation). As described by the manufac-
turer, the protocol results in two fractions: a ‘total cellular membrane
protein fraction’ and a ‘cytosolic fraction’; the former includes the
plasmamembrane and all organelle and other intracellularmembranes,
and hereafter is referred to simply as the ‘membrane fraction’.
Total protein concentration was determined using the Bradford
assay; membrane protein was diluted to 1 mg/mL and stored at
−20 °C until use. Protein samples were combined with Laemmli load-
ing buffer containing 100 mM DTT and heated at 55 °C for 5 min; this
protocol reduced aggregation compared to boiling with β-
mercaptoethanol. Protein (10 μg for brain tissue, 1 μg for cells) was
loaded in a 4–20% mini-Protean polyacrylamide gel (Bio-Rad
4561095) and run in SDS/Tris/glycine buffer (25 mM Tris-HCl,
250 mM glycine, 0.1% SDS) at 100 V for two hours. Proteins were then
Table 3
Antibody details.
Antibody Supplier Product code Batch mGlu3 epitope Concentration used
WB ICC ICH
mGlu3 Santa Cruz sc-47137 A0907 N-terminal domain 1:200 – –
mGlu3 Santa Cruz sc-47138 D1913 N-terminal domain 1:200 – –
mGlu3 Santa Cruz sc-47139 B2614 N-terminal domain 1:200 – –
mGlu3 Abcam ab10309 GR11670-6 Residues 118–126 1:500 – –
mGlu3 Abcam ab188750 GR230043-1
GR230043-2
N-terminal domain 1:1000 – –
mGlu3 Abcam ab166608 YJ100911CS 845-C terminus 1:50,000 1:5000 1:10,000
mGlu3 peptide Abcam ab208352 GR250252-1 Peptide for ab166608 – – 10 μg/mL
mGlu3Δ4 Cambridge Biomedicals Custom made TQGSHHPVSTPEEC 1:500 – –
mGlu3Δ4 peptide Cambridge Biomedicals Custom made TQGSHHPVSTPEEC 30 μg/mL – –
Βeta-actin Sigma A1978 011M4812 – 1:2,000,000 – –
N-Cadherin BD Biosciences 610920 78545 – 1:10,000 – –
GAPDH Abcam ab9484 GR165366–3 – 1:5000 – –
HRP goat anti-rabbit Biorad 172-1019 350003011 – 1:10,000 – –
HRP goat anti-mouse Biorad 172-1011 350003068 – 1:5000 – –
Alexa 568 goat anti- rabbit Invitrogen A11011 623962 – – 1:1000 1:1000
21A. García-Bea et al. / Schizophrenia Research 177 (2016) 18–27transferred to a PVDF membrane (Millipore) in Tris/glycine/methanol
buffer (25 mM Tris-HCl, 192 mM glycine, 20% methanol) at 25 V over-
night. The purity of the resulting membrane fraction was assessed
using anti-N-cadherin and anti-GAPDH antibodies (Table 3), at
1:10,000 and 1:5000 respectively.
PVDF membranes were blocked for 40 min at room temperature
with 5% skimmed milk diluted in phosphate-buffered saline with 0.1%
Tween (PBST). The primary and secondary antibody incubations were
performed at room temperature in PBST with 2% skimmed milk, for
1 h and 40min respectively.Wash steps before and after addition of sec-
ondary antibody consisted of three 10 min incubations in PBST, with a
ﬁnal 5 min wash in PBS prior to addition of Enhanced Chemilumines-
cence (ECL) reagent (GE Healthcare, Fisher Scientiﬁc, Loughborough,
UK) as per manufacturer's instructions. The blots were exposed to ﬁlm
(GE Healthcare) and digitally captured using an AlphaImager3400
system.
2.7. Immunocytochemistry and immunohistochemistry
The ab166608 antibodywas tested for use in immunocytochemistry
(in the HEK293T/17 cells) and for immunohistochemistry (in brain
sections).
HEK293T/17 cells grown in chamber slides were ﬁxed in parafor-
maldehyde (4% w/v in PBS) for 15 min at room temperature, washed
three times for 5 min in PBS, blocked and permeabilized for 40 min
with PBS containing 10% goat serumand 0.1% Triton-100X at room tem-
perature. The primary antibody incubation was performed for 1 h at
room temperature. Cells were then washed 3 times for 15 min in PBS
and incubated with secondary antibody (Alexa 568; Table 3) for 1 h at
room temperature, washed for 3 × 15min in PBS, then 2min in distilled
water, air dried and mounted in Vectashield Antifade Mounting Me-
dium with DAPI (Vector, H-1200).
Frozen 14 μm sections of mouse brain (n= 2–3 mice of each geno-
type) were ﬁxed in paraformaldehyde (4% w/v in PBS) for 15 min at
room temperature, and washed three times for 5 min in PBS. To reduce
autoﬂuorescence, sectionswere incubated for 15min in 50mMglycine,
and washed three times for 5 min in PBS. Sections were blocked and
permeabilized in PBS containing 10% goat serum and 0.3% Triton-100X
for 1 h at room temperature. Following an overnight incubation with
the primary antibody at 4 °C, sections were washed 3 times for 15 min
in PBS and incubated with secondary antibody (Alexa 568; Table 3)
for 1 h at room temperature. Finally sections were washed three times
for 15 min in PBS, then 2 min in distilled water, air dried and mounted
in Vectashield Antifade Mounting Medium with DAPI (Vector, H-1200). As a control, the ab166608 blocking peptide was diluted in
blocking solution, at a concentration ten times greater than the anti-
body, and co-incubated for two hours at room temperature with con-
stant agitation.
2.8. Study of mGlu3 immunoreactivity in schizophrenia
For the study ofmGlu3 in schizophrenia, the ab166608 antibodywas
used for western blotting, at 1:50,000. Quadruplicate samples of mem-
brane protein were used for each subject, run as two sets of duplicates
on consecutive days. To control for variability between days and gels,
two lanes of every gel contained an ‘internal’ protein standard made
from a pool of six individuals selected randomly from the brain series;
the demographic details of these subjects are shown in Supplementary
Table 1. The use of an internal standard has been advocated
(McCullumsmith and Meador-Woodruff, 2011) and used in prior stud-
ies in the ﬁeld (Crook et al., 2002; Corti et al., 2007). Beta-actin
(1:2,000,000) was measured as a control for protein loading; the abun-
dance of β-actin is reported to be unchanged in schizophrenia (Bauer
et al., 2009). The study was conducted and analysed blind to diagnosis,
genotype, and other demographic information.
Measurement of the bands was carried out using Image Studio Lite
software (LI-COR Biosciences, Cambridge, UK). Two ﬁlm exposure
times were used, to optimise measurement of monomer and dimer
bands, as these had different staining intensities, and to avoid ﬁlm satu-
ration. A box was drawn around each band and the total intensity (the
sum of the individual pixel intensities) was determined. The mean
value from the quadruplicate readings was used for the analysis. Results
for mGlu3 bands were normalised to the internal standards run on that
gel; the value for the standard was set to 100; the data presented here
are thus arbitrary units, relative to this value.
2.9. Statistical analysis
mGlu3 immunoreactivity was inspected for correlations with con-
tinuous variables (e.g. age, pH, post mortem interval [PMI]) using the
Pearson's coefﬁcient. Because signiﬁcant correlations of mGlu3 were
seen with these three factors, and the schizophrenia and control groups
differed signiﬁcantly in mean age, pH and PMI (Table 2), we selected a
sub-sample (‘matched sample’) which were matched on these vari-
ables. Diagnostic comparisons were made using this sub-sample by
ANOVA, with any variable still showing a signiﬁcant correlation in-
cluded as a covariate (see Suckling, 2011). For further details, see
Results.
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This study had two main components. First, we assessed several
commercially available anti-mGlu3 antibodies, and one novel antibody
directed at the mGlu3Δ4 variant, in knockout (versus wildtype)
mouse brain, and in transfected (versus un-transfected) HEK293T/17
cells, for western blotting. Second, we tested the onewell-validated an-
tibody for its suitability for immunohistochemistry, and used it for a
semi-quantitative immunoblotting study of mGlu3 in schizophrenia.
All western blot experiments, except where stated, were carried out
on the membrane fraction. Fig. 1 demonstrates that the protocol re-
sulted in the anticipated detection of the membrane protein N-
cadherin in the membrane but not cytosolic fraction, and enrichment
of GAPDH in the cytosolic fraction.
3.1. Initial characterisation of anti-mGlu3 antibodies
We ﬁrst tested the anti-mGlu3 antibodies to see whether they pro-
duced bands of the predicted size for mGlu3 (~90–100 kDa and
~200 kDa) in mouse brain. Three antibodies (sc-47137, sc-47139 and
ab10309) did not produce bands of these sizes but instead resulted in
several smaller bands, and with a similar banding pattern in
Grm2−/−/3−/− as in wild-type mice (data not shown). One antibody
(sc-47138) produced a band at ~90 kDa, as well as one at ~50 kDa;
both bands were seen equally in Grm2−/−/3−/− as well as wild-type
mice (Supplementary Fig. 1A). Hence, none of these antibodies showed
convincing evidence of binding to mGlu3 in our hands, and they were
not studied further.
One antibody, ab188750, directed against the N-terminus, detected
a strong band at ~200 kDa in wild-type mouse which was absent in
Grm2−/−/3−/− and Grm3−/−mice (Supplementary Fig. 1B). Moreover,
a bandof the same sizewas also seen in cells over-expressingGRM3 and
in human brain tissue. However, in addition, the antibody detected two
smaller bands (of ~60 kDa and ~45 kDa) which were present in
Grm2−/−/3−/− and Grm3−/− wild-type mice and hence non-speciﬁc;
the 60 kDa band was also seen in human brain. This antibody also
proved to give variable and sometimes weak staining (though with a
similar pattern) across experiments.
The ﬁnal antibody, ab166608, directed against the C terminus,
proved most successful (Fig. 2A). It produced two strong bands of theFig. 1. Characterisation of membrane and cytosolic fractions. Lane 1: membrane fraction,
N-cadherin. Lane 2: cytosol fraction, N-cadherin. Lane 3: membrane fraction, GAPDH.
Lane 4: cytosolic fraction, GAPDH. The blots show the predicted localisation of N-
cadherin to the membrane, and the enrichment of GAPDH in cytosol. Numbers are
molecular weight (kDa).predicted molecular weight for mGlu3 in mouse brain, and in
transfected HEK293T/17 cells, which were absent in Grm2−/−/3−/−
and Grm3−/−mouse brain and in un-transfected cells. No other bands
were seen. It also produced the same banding pattern in human brain.
Immunoreactivitywas concentrated inmembranes compared to the cy-
tosol (Fig. 2B).We therefore focused on this antibody for all subsequent
work.
3.2. Identiﬁcation of mGlu3Δ4 and characterisation of an anti-mGlu3Δ4
antibody
In a previous study (Sartorius et al., 2008), a GRM3 transcript iso-
form lacking exon 4 was identiﬁed. It was predicted to encode an
mGlu3 variant with a novel C-terminus (due to a frameshift) of molec-
ular weight of ~65 kDa, which we denote mGlu3Δ4. In this study, we
transfected HEK293T/17 cells with GRM3Δ4, resulting in a band of
this size for mGlu3Δ4 which was detected, as predicted, by the N-
terminal ab188750 antibody (Supplementary Fig. 1B, lane 6) but not
by the C-terminal ab166608 antibody (data not shown). We also tested
a potential novel mGlu3Δ4-selective antibody (since the antibody used
by Sartorius and colleagueswas not available), and found that it also de-
tected a band of approximately this size in transfected HEK293T/17
cells, as well as a larger band which may be a dimer (Fig. 3). These
bands were speciﬁc, in that they were not seen with peptide block, or
in un-transfected cells. No bands of similar sizes were detected in
human brain, either in superior temporal cortex or in other regions
tested (hippocampus, cerebellum, and cingulate cortex; data not
shown), despite using a range of experimental conditions. Moreover,
the antibody also detected a strong, smaller band (~60 kDa) which
was present in un-transfected cells, human brain tissue, and brain tissue
fromwild-typemice (which do not express this variant) and Grm2−/−/
3−/−mice, and which is therefore non-speciﬁc (Fig. 3).
3.3. Immunocytochemistry and immunohistochemistry using the ab166608
antibody
Since the cellular and subcellular localization of mGlu3 are of inter-
est, we used the ab166608 antibody in immunocytochemistry of
HEK293T/17 cells and immunohistochemistry in brain sections (Sup-
plementary Fig. 2).
In the over-expressing HEK293T/17 cells, we found robust cytoplas-
mic mGlu3 immunoreactivity with enhanced signal around the plasma
membrane. No immunoreactivity was seen in un-transfected cells, or in
the absence of primary antibody. However, in wild-type mouse brain,
diffuse neuropil immunostaining was seen, with sparing of neuronal
cell bodies. The immunostaining was speciﬁc, as deﬁned by the fact
that it was abolished by the blocking peptide and not seen with omis-
sion of the primary antibody. A similar pattern of results was also seen
in sections of human brain (data not shown). However, critically, in
Grm2−/−/3−/− mouse brain, a different pattern was observed, with
strong immunoreactivity concentrated over cells, particularly around
the plasmamembrane, andwithmuch less neuropil staining. This strik-
ing (but artefactual) staining was consistent in different wild-type and
Grm2−/−/3−/−mice.
3.4. mGlu3 immunoreactivity in human brain
We used the C-terminal antibody for quantitative assessment of
mGlu3 immunoreactivity in human superior temporal cortex
(Table 2) using western blots.
mGlu3 immunoreactivity correlated negatively with age at death
and PMI and positively with pH. This applied to dimeric andmonomeric
forms, and to control and schizophrenia groups considered separately
(Table 4 and Fig. 4A). mGlu3 immunoreactivity was higher in men
than women, both for the dimer (145 ± 38 vs. 127 ± 35; t= 2.94, d.f.
154, p = 0.004) and the monomer (205 ± 79 vs. 173 ± 68; t = 2.50,
Fig. 2.Western blotting with ab166608 antibody. Panel A: Immunoblotting proﬁle in membranes. Lane 1: Wild-type mouse brain. 2: Grm2−/−/3−/− double knockout mouse brain. 3:
Wild-type mouse brain. 4: Grm3−/− knockout mouse brain. 5: Rat brain. 6: Human superior temporal cortex. 7: Transfected HEK293T/17 cells. Lanes 1, 3, and 5–7 show the selective
detection of two immunoreactive bands at the molecular weights predicted for monomeric and dimeric mGlu3 (~100 kDa and ~200 kDa respectively). The bands are speciﬁc to
mGlu3 as judged by their absence in Grm2−/−/3−/− and Grm3−/− mice (lanes 2 and 4). Panel B: Staining with ab166608 antibody is concentrated in the membrane fraction (lane
8) relative to the cytosol (lane 9); note the latter also lacks a band corresponding to the dimer. Numbers are molecular weight (kDa).
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the control and schizophrenia groups considered separately (data not
shown). There were no effects of race, hemisphere, brain weight,
smoking history, nor ethanol level, on mGlu3 immunoreactivity (data
not shown).Fig. 3.Western blotting with a novel mGlu3Δ4 antibody. 1: HEK293T/17 cells transfected
with GRM3Δ4 cDNA. 2: Human superior temporal cortex. 3: Untransfected HEK293T/17
cells. 4: Wild-type mouse brain. 5: Grm2−/−/3−/− mouse brain. 6: HEK293T/17 cells
transfected with GRM3Δ4 mRNA in presence of blocking peptide. 7: Human superior
temporal cortex, in presence of blocking peptide. The bands at ~65-70 kDa and
~140 kDa are speciﬁc, being seen in transfected cells (lane 1) but not in untransfected
cells (lane 3) nor with the blocking peptide (lane 6). No bands of this weight are seen in
human brain (lane 2). There is an additional band at ~60 kDa which is not detecting
mGlu3Δ4 (as judged by its presence in lanes 3–5), despite being abolished by the
blocking peptide (lanes 6 and 7). Numbers are molecular weight (kDa).3.5. mGlu3 immunoreactivity in schizophrenia
Because of the correlations of mGlu3 immunoreactivity with age, pH
and PMI, and the fact that these variables differed signiﬁcantly between
controls and cases in thewhole samplewhichwould confound their use
as covariates (Table 2), we performed our case-control comparisons on
a sub-sample (of 63 controls and 46 patientswith schizophrenia)which
was matched on these variables (a ‘matched’ series; Table 2). Within
this sub-sample, mGlu3 immunoreactivity still correlated negatively
with age, and equivocally with PMI, but not with pH. Our primary
group comparisons therefore included age and PMI as covariates.
Representative gels are shown in Fig. 5, and the results for mGlu3
immunoreactivity in schizophrenia compared to the control subjects
are shown in Fig. 4. Neither mGlu3 dimer (Fig. 4B) nor monomer (Fig.
4C) differed between the groups (dimer: F1, 105 = 2.53, p = 0.115;
monomer: F1, 105 = 0.43, p = 0.51). Nor was a diagnostic effect ob-
served for the dimer: monomer ratio (F1, 105 = 0.09, p = 0.77) or for
the sum of dimer and monomer bands (data not shown). Beta-actin,
used as a loading control, did not differ between groups, and a negative
result was also seen if mGlu3 was normalised to beta-actin rather than
to the internal pooled standard (data not shown). Note in Fig. 4 that the
y axis units are relative to the internal standard, which was set to 100
(see Section 2.8). It is thus apparent that both case and control groups
had mean band densities greater than the mean of the six subjects
who were used to generate the internal standard. However, this issue
did not lead to ﬁlm saturation or a ‘ceiling effect’, since longer exposuresTable 4
Correlations of mGlu3 immunoreactivity with age, pH and post mortem interval (PMI).
Whole sample
(N= 157)
Controls
(N= 87)
Schizophrenia
(N= 70)
Dimer Monomer Dimer Monomer Dimer Monomer
Age (y) −0.360⁎⁎⁎ −0.368⁎⁎⁎ −0.411⁎⁎⁎ −0.341⁎⁎ −0.321⁎⁎ −0.414⁎⁎⁎
pH +0.328⁎⁎⁎ +0.232⁎⁎ +0.412⁎⁎⁎ +0.264⁎⁎ +0.232 +0.167
PMI (h) −0.249⁎⁎ −0.179⁎ −0.270⁎ −0.153 −0.236⁎ −0.200
Values are Pearson coefﬁcients.
⁎ P b 0.05.
⁎⁎ P b 0.01.
⁎⁎⁎ P b 0.001.
Fig. 4.mGlu3 immunoreactivity in human superior temporal gyrus in relation to age and
schizophrenia. A: Dimeric mGlu3 is inversely correlated with age. B: Dimeric mGlu3 in
control subjects (ﬁlled circles) and subjects with schizophrenia (unﬁlled circles). C:
Monomeric mGlu3 in control subjects (ﬁlled circles) and subjects with schizophrenia
(unﬁlled circles). There are no differences between groups. Line in A shows correlation;
lines in B and C show uncorrected means. In all panels, the y-axis units are mGlu3
immunoreactivity relative to the internal standards, which were set at 100.
Fig. 5.Representativewesternblots from the comparison of control subjects and subjectswith s
C3) and three schizophrenia subjects (S1–S3). This exposure was used for quantitation of the
quantitation of the lower and weaker monomer band.
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occurred, we would not have observed the correlations of mGlu3 with
age, postmortem interval and pH (Table 4). The disparity in band inten-
sities between the internal standard pool and the experimental samples
likely arose for two reasons. First, compared to the brain series as a
whole, the six subjects used for the internal standards had, by chance,
a greater age, longer post mortem interval, and lower pH (Supplemen-
tary Table 1 and Table 2); all of these factors are associatedwith reduced
mGlu3 immunoreactivity (Table 4). Second, the samples used for the in-
ternal standards had undergone three freeze-thaw cycles, whereas the
study samples had only one. Given the equivocal sex dimorphism in
mGlu3 immunoreactivity noted above, we repeated the ANOVAs with
sex as an additional factor; no main effect of sex, nor a diagnosis-by-
sex interaction, was seen for either dimer or monomer (data not
shown). However, in a post hoc analysis, mGlu3 dimer was increased
in men with schizophrenia compared to male controls (156 ± 38 vs.
143 ± 35; F1, 74 = 3.91, p = 0.050), with no difference for women
(134 ± 36 vs. 129 ± 26; F1, 27 = 0.32, p= 0.57).
Within the full schizophrenia sample, monomeric mGlu3 was nega-
tively correlated with age at onset of illness (N = 70; R = −0.321,
p b 0.01); however this correlation was weaker and non-signiﬁcant in
the sub-sample used for case-control comparisons (N = 46;
R=−0.171, p=0.25). Monomeric and dimeric mGlu3 correlated neg-
atively and signiﬁcantly with duration of illness (in the full sample, and
in the matched sample), but these correlations disappeared when
partialling for age at death (data not shown). mGlu3 immunoreactivity
did not correlate with any indices of antipsychotic exposure (last re-
corded dose; cumulative exposure), nor did it differ between those
with positive and negative toxicology, nor was it inﬂuenced bywhether
the patient had died by suicide or natural causes (data not shown).
3.6. mGlu3 and GRM3 genotype
We assessed whether rs10234440 genotype predicted mGlu3 im-
munoreactivity. Because of the low frequency of the rare (C) allele, we
compared TT homozygotes with C carriers for this analysis. We found
no effect of genotype on monomeric or dimeric mGlu3 (Table 5). Nei-
ther did we ﬁnd any genotype-by-diagnosis interactions (data not
shown).
4. Discussion
4.1. Characterisation of antibodies
It is increasingly recognised that many antibodies used as experi-
mental tools have not been sufﬁciently well characterised, and there
are many examples of false positive and unrepeatable ﬁndings, as well
as the expenditure of time and money on antibodies which fail to per-
form as the vendor claimed (Saper and Sawchenko, 2003; Rhodes and
Trimmer, 2006). These issues affect receptors of interest in schizophre-
nia research, including mGlu1 receptors (Ayala et al., 2012) andchizophrenia. A: Example of a gel, containing duplicate standards (Std), three controls (C1–
dimer (upper band). The bottom band is beta-actin. B: Same gel, at longer exposure, for
Table 5
mGlu3 immunoreactivity and rs10234440 genotype.
TT homozygotes C carriers
Whole sample N = 120 N = 35
Monomer 196 (81) 185 (66)
Dimer 141 (39) 132 (30)
Controls N = 65 N = 21
Monomer 202 (85) 182 (67)
Dimer 143 (40) 128 (31)
Schizophrenia N = 55 N = 14
Monomer 188 (74) 190(66)
Dimer 137 (39) 139 (29)
Values are mean (SD) normalised to internal standard (arbitrary units). There are no dif-
ferences between groups.
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target proteins. Reﬂecting these concerns, there are calls for more care-
ful, multifaceted, and method-speciﬁc validation of antibodies
(Holmseth et al., 2006; Lorincz and Nusser, 2008; Bordeaux et al.,
2010; Baker, 2015). Amongst other considerations, appropriate charac-
terisation should include demonstration that the antibody binds specif-
ically and selectively to band(s) of the predicted molecular weight of
the target protein when present, and with absence of signal when the
target protein is absent. These criteria are most readily assessed by
showing that immunoreactivity is present in a wild-type mouse but
not in a mouse with the encoding gene knocked out (constitutively or
conditionally), and by showing that the bands are seen when cells are
transfected with the encoding gene and thence express the protein.
To our knowledge, no commercially available anti-mGlu3 antibodies
have previously been characterised using either approach; the one ex-
ception in schizophrenia is provided by Corti et al. (2007) but their
anti-mGlu3 antibodywas generated in-house andnot available to others.
Our present results conﬁrm that, in our hands and for the batch(es) and
experimental conditions used, several anti-mGlu3 antibodies fail, as
judged by bands of thewrong size and/or bandswhich are not abolished
in Grm3−/− or Grm2−/−/3−/− mice. We also had similar experiences
with other anti-mGlu3 and anti-mGlu2/3 antibodies tried previously
(TAL and PJH, unpublished observations). One antibody tested here,
ab188750, did successfully detect a speciﬁc band at ~200 kDa, the puta-
tive mGlu3 dimer, and therefore could be used for immunoblotting for
that target. However, it did not detect the mGlu3 monomer, and also
detected non-speciﬁc smaller bands, limiting its utility.
Hence, of the six anti-mGlu3 antibodies tested, only one (ab166608)
met our criteria in knockoutmice, and in transfected cells, and in human
brain. Using this antibody, we made several observations. Firstly, we
conﬁrm the presence of two bands for mGlu3; one being the predicted
molecular weight of the full length protein (~95 kDa); we (and others;
Corti et al., 2007) assume the second, and more intense, band at
~200 kDa is a homodimer, as occurs for many other GPCRs, and with
the dimer being the primary functional unit (El Moustaine et al.,
2012). It is interesting that the N-terminal antibody (ab188750) only
detected the dimer (in membranes); we have no explanation but spec-
ulate that this reﬂects a conformational change such that the epitope is
only exposed when in dimeric form.
Despite its validation for western blots, we did not ﬁnd ab166608
suitable for immunohistochemistry in brain tissue because of the signal
seen in Grm2−/−/3−/−mice. Notably, this latter signal appeared plausi-
ble, with enhanced staining around the cell membrane, consistent with
the membrane enrichment seen in the western blots. These observa-
tions highlight the need for caution and for additional immunohisto-
chemical controls even for antibodies validated by immunoblotting
(Holmseth et al., 2006; Rhodes and Trimmer, 2006; Baker, 2015). We
did not pursue more detailed strategies, such as pepsinisation, or anti-
gen retrieval, whichmight have permitted different and more valid im-
munohistochemical ﬁndings, aswas reported for anti-mGlu2 antibodies
(Lorincz and Nusser, 2008).4.2. Factors affecting mGlu3 immunoreactivity in human brain
A decline with age has been reported for frontal cortex mGlu3 im-
munoreactivity (Corti et al., 2007) and for GRM3 mRNA (Colantuoni
et al., 2008). Age-related reductions are also seen in this region for
mGlu2/3 binding site density (Frank et al., 2011) and for mGlu2/3 im-
munoreactivity in controls but not in schizophrenia subjects (Crook
et al., 2002). Our ﬁndings (Table 4 and Fig 4A) conﬁrm that there is a ro-
bust decrease of mGlu3 across adulthood in human brain, occurring in
superior temporal cortex as well as prefrontal cortex. It is unknown
whether the reduction occurs equally in all cells or compartments ex-
pressing mGlu3, or occurs preferentially in one or other location (e.g.
in glia, or presynaptically). Our failure to identify an anti-mGlu3 anti-
body suitable for immunohistochemistry in human brain complicates
investigation of this issue.
Correlations between gene expression and pH, and to a lesser extent
PMI, are well recognised for mRNAs. The present data emphasise that,
despite generally greater stability of proteins to such factors (Harrison
et al., 1995; Stan et al., 2006), similar concerns can apply to protein
products (Wang et al., 2000; Eastwood and Harrison, 2001; Ferrer
et al., 2007), in this case mGlu3 (Table 4). Thus demographic and
perimortem factors require careful attention in quantitative western
blot (or immunohistochemical) studies, with inspection for the pres-
ence of correlations, matching for variables between groups, and appro-
priate statistical control for their inﬂuence. In the current study, these
issuesmandated the selection of a subgroup of thewhole sample. Fortu-
nately, the initial sample sizemeant that the subgroupwas still substan-
tial, and considerably larger than all prior studies of mGlu3 in
schizophrenia.
4.3. mGlu3 immunoreactivity in relation to schizophrenia and GRM3
genotype
Previous studies of mGlu3 immunoreactivity in schizophrenia had
not produced a consistent pattern of results (Table 1), and studies of
GRM3 mRNA had similarly not revealed clear evidence of altered ex-
pression (Harrison et al., 2008; Sartorius et al., 2008). ThemGlu3 studies
were limited by the fact that two studies had used antibodies which
cross-reacted with mGlu2 (Crook et al., 2002; Gupta et al., 2005), and
one used an anti-mGlu3 antibody with only limited characterisation
(Ghose et al., 2009), and all three were relatively limited in sample
size. The study by Corti et al. (2007) had the merit of a larger sample
(35 controls, 20 cases), and the use of a novel anti-mGlu3 antibody
which had been validated in Grm3−/−mouse brain. Their main ﬁnding
in schizophrenia was a reduction in the putative dimeric form of mGlu3
in prefrontal cortex, without any alteration in the monomer. However,
we did not replicate this result in our sample (63 controls, 46 cases),
ﬁnding no change in either mGlu3 immunoreactive band. Clearly, we
cannot extrapolate our results beyond the superior temporal cortex,
but overall the data support the conclusion that there are no alterations
inmGlu3 expression in schizophrenia. Our data did suggest the possibil-
ity of an increase inmGlu3 dimer immunoreactivity inmenwith schizo-
phrenia, but we do not view this as robust in the absence of a diagnosis-
by-sex interaction, or any prior reason for predicting such a result. The
absence of any correlations between mGlu3 and medication exposure,
or smoking history, suggests that the lack of any diagnostic difference
in mGlu3 immunoreactivity does not arise from antipsychotic- or
smoking-induced normalisation of an underlying change in mGlu3
immunoreactivity.
Our study used total membrane protein extracted from homoge-
nates of the superior temporal cortex of patients with chronic schizo-
phrenia. It remains possible that in schizophrenia there are localised
alterations (e.g. in particular cell populations, or in other brain regions),
or changeswhich occurred prior to the onset of illness, orwhich are lim-
ited to particular phases of the illness (c.f. the possibility that mGlu2/3
agonists are effective early but not late in the disease; Kinon et al.,
26 A. García-Bea et al. / Schizophrenia Research 177 (2016) 18–272015; Krystal and Anticevic, 2015). Another possibility not addressed by
the current methodology is that the subcellular distribution of mGlu3 is
altered in schizophrenia; for example, there could be a shift between
pre- and post-synaptic domains, or between intracellular and plasma
membranes. Indeed, the latter has been reported for ionotropic gluta-
mate receptors and other proteins, indicative of aberrant trafﬁcking
(Hammond et al., 2010, 2012; Kristiansen et al., 2010). Investigating
whether this also occurs for mGlu3 would be of interest, but would re-
quire much more complex fractionation procedures than used here
(Behan et al., 2009; Hahn et al., 2009; McCullumsmith and
Meador-Woodruff, 2011), and would be challenging to implement in
such a large series of brains. A complementary approach to study the in-
tracellular distribution of mGlu3 would be to use immunohistochemis-
try, but the unsuitability of ab166608 precluded this method. Finally,
there could also be functional effects onmGlu3 signalling in schizophre-
nia which are independent of receptor abundance, for example differ-
ences in heterodimerisation with other receptors (Gonzalez-Maeso
et al., 2008; Doumazane et al., 2011), or the coupling of mGlu3 to G-
proteins and other downstream effectors (Salah-Uddin et al., 2009).
The GRM3 polymorphism we studied did not inﬂuence mGlu3 im-
munoreactivity. The SNP, rs10234440, is within the GRM3 locus which
shows genome-wide association to schizophrenia (Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014). The
negative result therefore provides no evidence that the risk locus
operates bymodulating GRM3 expression, and alternative explanations
should be sought. However, there are many caveats to this conclusion.
For example, the risk variant is intronic and hence may alter splicing
rather than transcription (as suggested by the earlier study which
found an association between a GRM3 risk SNP and the GRM3Δ4
mRNA isoform; Sartorius et al., 2008). However, we were unable to in-
vestigate this possibility in terms of the abundance of the encoded
mGlu3Δ4 variant, because the new antibody generated against this se-
quence proved unsuccessful, failing to detect the variant in human
brain tissue but instead detecting a smaller and non-speciﬁc band.
Other possible mechanisms of genetic association include modulation
of an antisense GRM3 transcript (Buonaguro et al., 2015), or effects of
genotype on mGlu3 which are limited to speciﬁc locations or develop-
mental stages, as is the case for some other schizophrenia risk genes
(Kleinman et al., 2011; Birnbaum et al., 2014; Paterson et al., 2014;
Tao et al., 2014).
5. Conclusions
We draw two main conclusions from this work. The ﬁrst is that
many antibodies available to study mGlu3 are non-speciﬁc as judged
using knockout mice and other experimental controls. Hence the
value of such mice – as well as cell transfection and overexpression –
as part of a comprehensive antibody characterisation is highlighted.
Without this information, there is a signiﬁcant potential for misleading
ﬁndings using immunoblotting (and immunohistochemistry). The sec-
ond conclusion is that the abundance of membrane-bound mGlu3 is
not altered in the superior temporal cortex in schizophrenia. This is a ro-
bust conclusion, given the large sample size, and the use of a well-
validated, speciﬁc antibody. However, it leaves open the possibility of
more nuanced alterations inmGlu3 expression, and of aberrant receptor
signalling, in the disorder. These possibilities are worth pursuing, given
the evidence that GRM3 contributes to the genetic risk for schizophre-
nia, and in light of the continuing focus on group II metabotropic gluta-
mate receptors as therapeutic targets.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2016.04.015.
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